TABLE 4.
Multivariate logistic regression analyses for the presence of CAD.
| Variables | Model 1 |
p-value | Model 2 |
p-value | Model 3 |
p-value | |||
| OR | 95% CI | OR | 95% CI | OR | 95% CI | ||||
| Age (years) | 1.08 | 1.05–1.10 | <0.001 | 1.08 | 1.05–1.10 | <0.001 | 1.08 | 1.06–1.10 | <0.001 |
| Male, n (%) | 2.24 | 1.45–3.47 | <0.001 | 2.30 | 1.48–3.58 | <0.001 | 2.10 | 1.35–3.26 | 0.001 |
| Glucose metabolism status | |||||||||
| NGR | Reference | Reference | Reference | ||||||
| PDM | 2.02 | 1.03–3.94 | 0.040 | 2.04 | 1.03–4.03 | 0.041 | 1.74 | 0.88–3.43 | 0.113 |
| DM | 1.89 | 0.84–4.23 | 0.123 | 1.81 | 0.80–4.10 | 0.158 | 1.94 | 0.85–4.43 | 0.118 |
| Hypertension | 1.17 | 0.78–1.74 | 0.445 | 1.18 | 0.79–1.77 | 0.406 | 1.04 | 0.69–1.57 | 0.859 |
| eGFR (mL/min/1.73 m2) | 1.00 | 0.99–1.01 | 0.818 | 1.00 | 0.99–1.01 | 0.820 | 1.00 | 0.99–1.01 | 0.764 |
| UA (μmol/L) | 1.00 | 1.00–1.01 | 0.023 | 1.00 | 1.00–1.01 | 0.015 | 1.00 | 1.00–1.01 | 0.065 |
| Single antiplatelet therapy | 2.89 | 1.25–6.71 | 0.013 | 2.90 | 1.25–6.70 | 0.013 | 2.94 | 1.26–6.88 | 0.013 |
| Statin | 0.84 | 0.37–1.90 | 0.673 | 0.82 | 0.36–1.84 | 0.624 | 0.86 | 0.37–1.98 | 0.723 |
| Insulin | 1.03 | 0.39–2.75 | 0.948 | 1.02 | 0.39–2.71 | 0.966 | 0.86 | 0.31–2.35 | 0.766 |
| Other hypoglycemic drugs | 3.09 | 1.05–9.10 | 0.041 | 3.07 | 1.04–9.06 | 0.042 | 2.64 | 0.88–7.92 | 0.082 |
| TG/HDL-C ratio (Per SD) | 1.32 | 1.02–1.70 | 0.033 | – | – | ||||
| TyG index (Per SD) | – | 1.28 | 0.84–1.95 | 0.256 | – | ||||
| METS-IR (Per SD) | – | – | 1.65 | 1.32–2.05 | <0.001 | ||||
p-values in bold are <0.05.
OR, odds ratio; CI, confidence interval; NGR, normal glucose regulation; PDM, prediabetes mellitus; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; UA, uric acid; TG/HDL-C ratio, the ratio of triglycerides to high-density lipoprotein cholesterol; TyG index, triglyceride and glucose index; METS-IR, metabolic score for insulin resistance.